Teva Pharmaceuticals Industires Limited | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Teva Pharmaceuticals Industires Limited

Sort by

Viewing results 1‒24 of 24

LexJonathan Guthrie
The Lex Newsletter: deus ex machina moments elevate tech and pharma Premium content
...Generics have been the métier of Teva rather than genetics. It is here that the story starts darkening....
August 25, 2023
LexDrug prices
Generic drug costs: a partial cure Premium content
...High prices reward developers for a time-limited period, after which copy cats are free to drive prices down....
August 26, 2020
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
US & Canadian companies
Hospitals in US sound alarm on impending chemotherapy shortages
...Pfizer is the sole supplier of vincristine, while Teva makes a branded version of the medicine known as Vincasar....
May 9, 2018
European equities
Stocks to watch: Kingfisher, AstraZeneca, Imperial Brands, Roche
...We expect limited immediate change from President Trump’s blueprint to lower drug prices....
May 25, 2018
News in-depthThe Big Read
US seeks a fix for its opioid addiction
...Among the most commonly named defendants are drugmakers such as Purdue Pharmaceuticals, which is privately owned, Johnson & Johnson, Allergan, Mallinckrodt, Endo and Teva; distributors such as McKesson,...
September 11, 2017
Due Diligence
Liliane Bettencourt’s death could transform L’Oréal and Nestlé Premium content
...Haruvi Snir will start later this year and joins from Israel's Teva Pharmaceutical. She will report to Nigel Sheail, head of business development....
September 22, 2017
FT Live
Global Private Banking Awards 2024
Celebrating excellence in wealth management
Thursday, 7 NovemberThe Landmark London, London, UK
US & Canadian companies
Allergan steps out of Pfizer ashes with $7bn of deals
...The company is already repurchasing $5bn of its shares, but Ms Rubin argues that this is “having limited impact in terms of its share price”....
October 6, 2016
Letter
UK government must reinforce its commitment to science
...Dr William Watson Head of Business Development, Teva Europe Professor Michael Wakeham Director, The Babraham Institute Sarah Lindsell Chief Executive, The Brain Tumour Charity Francine Bates Chief...
September 7, 2015
US & Canadian companies
Week in Review, April 11
...The limited synergies mean that FedEx is far more likely to succeed in completing its deal than UPS was in its attempted takeover....
April 10, 2015
Pharmaceuticals sector
Teva names Vigodman as chief executive
...“Considering the quite complex situation Teva is involved in now . . . the opportunities to bring in high-profile pharma veterans [from overseas] was limited,” said Jonathan Kreizman, head of research at...
January 9, 2014
US & Canadian companies
Tax thread runs through pharma deals
...The tactic is not limited to drugmakers, but for many sectors it remains an unrealistic option....
April 7, 2014
FT AlphavilleDavid Keohane
The 6am London Cut
...(Financial Times) Teva is facing a fresh confrontation with shareholders after Benny Landa, an Israeli entrepreneur and activist investor who has led the campaign for reform at Teva, urged shareholders...
July 15, 2014
Pharmaceuticals sector
Teva buys Japanese drugmaker for $460m
...Teva’s annual sales in Japan, where it operates a joint venture with pharmaceutical company Kowa, are more than $200m....
May 16, 2011
European companies
Novartis steals march with copycat move
...We expect the impact from biosimilars on MabThera to be limited and are confident with our strong pipeline we can compensate well.”...
January 11, 2011
Medicine patents: Drugmakers find it hard to do business
...Those companies could significantly build on their limited share of Japan’s $80bn pharmaceutical market, the world’s second-largest, analysts say....
February 24, 2011
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
US downturn
Shire settles dispute with Teva
...Shire, the Irish domiciled pharmaceutical company, has settled a legal dispute with Teva, the world’s largest generic drugs group, triggered by tight government controls on the supply of the stimulant amphetamine...
December 2, 2009
UK companies
Grandma knows best when it comes to drugs
...“[Brands] can stagnate and if you’re only waiting for people who already know about it you’re obviously going to have a limited market.”...
November 14, 2009
Pharmaceuticals sector
EU probe finds companies block cheap drugs
...More than 10 per cent were “reverse payment settlements” which limited the entry of generic medicines and involved payments from the originator to the generics....
November 28, 2008
News in-depthGlobal Economy
A bigger dose: Why generic drug producers are bulking up
...“The headroom for innovation is still limited,” says Brian Ager, head of Efpia, the European pharmaceutical industry trade association, who argues that there should be deeper discounts to create more savings...
July 22, 2008
US downturn
Wall St pares losses as oil retreats
...Gains for Teva Pharmaceutical and Research in Motion gave the Nasdaq a boost. Teva stock jumped 5.3 per cent to $44.74, after it reported positive results for a treatment for Parkinson’s disease....
June 16, 2008
FT AlphavilleGwen Robinson
UK buy-out firm leads $5bn chase for Merck arm
...Other bidders still in the frame include Teva Pharmaceuticals of Israel and Mylan Laboratories of the US. The three bidders have been told to submit final offers in two weeks, The Times said....
May 9, 2007
European companies
Bids for Merck’s generics arm rise above €4bn
...a definitive decision to proceed with the sale has yet to be made, and one individual with knowledge of the process said on Monday that the financial information made available to the bidders remained limited...
April 30, 2007
Asia-Pacific equities
Hospira to buy Australia’s Mayne for $2bn
...It marks the latest chapter in the consolidation of the generic drugs sector, which has witnessed Teva’s $7.4bn takeover of Ivax, and Barr Pharmaceuticals’ purchase of Croatia’s Pliva for $2.5bn....
September 21, 2006
European companies
‘Biosimilars’ target a market of $50bn
...Jonathan Kwok, analyst at Panmure, believes biosimilars will initially be limited to the few first-generation drugs that are, in biological terms, relatively simple, limiting the short-term impact on the...
February 17, 2006

Previous pagePage 1 of 1Next page